3-Iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 24, 2003, Pages 4309-4312

  Benjahad, Abdellah ^a   Guillemont, Jérôme ^b   Andries, Koen ^c   Nguyen, Chi Hung ^a   Grierson, David S ^a  

^a CNRS   (France)

^b Johnson Johnson P   (France)

^c Johnson Johnson P   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

3 DIMETHYLAMINO 4 BENZYLPYRIDINONE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DELAVIRDINE; EFAVIRENZ; EMIVIRINE; GCA 186; NEVIRAPINE; PYRIDONE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG POTENCY; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; MICHAEL ADDITION; NONHUMAN; POLYMERIZATION; REACTION OPTIMIZATION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; VIRUS MUTANT; VIRUS STRAIN; WILD TYPE;

HUMAN IMMUNODEFICIENCY VIRUS 1; STAPHYLOCOCCUS PHAGE 3A;

EID: 0344927100     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.09.045     Document Type: Article

References (16)

1. Gallant J.E. J. Clin. Virol. 25:2002;317.
2. Rossum A., Fraaij P., De Groot R. Lancet Infect. Dis. 2:2002;93.
3. Carr A., Cooper D.A. Lancet. 356:2000;1423.
4. Iversen A.K., Shafer R.W., Wehrly K., Winters M.A., Chesebro B., Merigan T.C., Mullins J.I. J. Virol. 70:1996;1086.
5. (a) Carr A., Samaras K., Thorisdottir A., Kaufmann G.R., Ghisholm D.J., Cooper D.A. Lancet. 353:1999;2093 (b) Jain R.G., Furfine E.S., Pednrault L., White A.J., Lenhard J.M. Antiviral Res. 51:2001;151.
6. (a) Mao C., Sudbeck E.A., Venkatachalam T.K., Uckun F.M. Biochem. Pharmacol. 60:2000;1251 (b) De Clercq E. Biochim. Biophys. Acta. 1587:2002;258.
7. Dollé V., Fan E., Nguyen C.H., Aubertin A.-M., Kirn A., Andreola M.L., Jamieson G., Tarrago-Litvak L., Bisagni E. J. Med. Chem. 38:1995;4679.
8. Dollé V., Nguyen C.H., Legraverend M., Aubertin A.-M., Kirn A., Andreola M.L., Ventura M., Tarrago-Litvak L., Bisagni E. J. Med. Chem. 43:2000;3949.
9. Bishop R.R., Clavell E.A.S., Chapman N.B. J. Chem. Soc. 1952;437.
10. El-Mariah F.A., Kappe T. Croatica Chem. Acta. 59:1986;171.
11. Kokil P.B., Nair P.M. Tetrahedron Lett. 28:1977;4113.
12. 50, μM) to achieve 50% protection of MT-4 cells from HIV-1 cytopathicity as determined by the MTT method (Pauwels, R.; Balzarini, J.; Baba, M.; Snoek, R.; Schols, D.; Herdewijn, P.; Desmyter, J.; De Clercq, E. J. Virol. Methods 1988, 20, 309). Unless noted otherwise, the LAI strain of HIV-1 was the infecting virus. Other infecting mutant (in the reverse transcriptase) strains of virus are characterised in the tables by the mutated amino acid position and the one letter codes. For instance, 181C refers to replacement of tyrosine at position 181 with cysteine. All determinations are average values for three or more tests. (b) nd, not determined.
13. Tanaka H., Takashima H., Ubasawa M., Sekiya K., Inouye N., Baba M., Shigeta S., Walker R.T., De Clercq E., Miyasaka T. J. Med. Chem. 38:1995;2860.
14. Hopkins A.L., Ren J., Tanaka H., Baba M., Okamato M., Stuart D.I., Stammers D.K. J. Med. Chem. 42:1999;4500.
15. Hsiou Y., Ding J., Das K., Clark A.D. Jr., Boyer P.L., Lewi P., Janssen P.A.J., Kleim J.-P., Rosner M., Hughes S.H., Arnold E. J. Mol. Biol. 309:2001;437.
16. Tanaka H., Baba M., Hayakawa H., Sakamaki T., Miyasaka T., Ubasawa M., Takashima H., Sekiya K., Nitta I., Inouye N., Shigeta S., Walker R.T., Balzarini J., De Clercq E. J. Med. Chem. 34:1991;349.